Financial returns on r&d: Looking back at history, looking forward to adaptive licensing

Reviews on Recent Clinical Trials

Volumn 10, Issue 1, 2015, Pages 28-43

  Scannell, J W ^a,b   Hinds, S ^c   Evans, R ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c SSR Health LLC   (United States)

Author keywords

Adaptive Licensing; AMR; Antimicrobial resistance; Clinical trial costs; Drug development; Drug discovery; R D productivity

Indexed keywords

FINGOLIMOD; RIMONABANT;

ADAPTIVE LICENSING; ARTICLE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG INDUSTRY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; INVESTMENT; LICENSING; LIFE CYCLE; ORGANIZATION AND MANAGEMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; DRUG CONTROL; DRUG DEVELOPMENT; ECONOMICS; GREAT BRITAIN; HISTORY; RESEARCH; THEORETICAL MODEL; TRENDS;

DRUG AND NARCOTIC CONTROL; DRUG DISCOVERY; GREAT BRITAIN; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MODELS, THEORETICAL; RESEARCH;

EID: 84930590869     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887110666150430151751     Document Type: Article

References (79)

1. [1] Hamilton M, Dorsey E, Matheson D, Thier S. Financial anatomy of biomedical research. JAMA - J Am Med Assoc 2005; 294: 1333-42.
2. [2] Congressional Budget Office. Research and Development in the Pharmaceutical Industry. Congress of the United States. 2006.
3. [3] Dorsey E, Thompson J, Carrasco N, et al. Financing of U.S. biomedical research and new drug approvals across therapeutic areas. PLoS One 2009; 4: e7015.
4. [4] Dorsey E, de Roulet J, Thompson J, et al. Funding of US biomedical research, 2003-2008. JAMA - J Am Med Assoc 2010; 303: 137-143.
5. [5] SSR Health. Below Zero and Falling Fast: R&D Productivity as an Enterprise Wide Crisis. Stamford (CT): SSR Health LLC 2011.
6. [6] SSR Health. Biopharmaceutical R&D Productivity: Metrics, Benchmarks and Rankings for the 22 Largest (by R&D Spending) US-Listed Firms. Stamford (CT): SSR Health LLC 2014.
7. [7] Deloitte UK Centre for Health Solutions. Measuring the Return from Pharmaceutical Innovation 2013. Weathering the Storm? Deloitte UK Centre for Health Solutions, London. 2013.
8. [8] Scannell JW, Anderson T, Porges G. Global Pharmaceuticals: Someone is Very Wrong about the Returns on R&D. New York (NY): Sanford C Bernstein LLC. 2011.
9. [9] Lowe D. Amgen Cuts Hard. Pipeline Corante. 2014; Available from: http://pipeline.corante.com/archives/2014/07/30/amgen_cuts_hard.php [cited: Oct 2014].
10. [10] Herper M. Valeant Pharma's Arguments about Drug Research are Misleading and Wrong. Forbes. 2014; Available from: http://www.forbes.com/sites/matthewherper/2014/06/12/valeantpharmas-arguments-about-drug-research-are-misleading-andwrong/[cited: Oct 2014].
11. [11] Munos BH. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009; 8: 959-68.
12. [12] Scannell J, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012; 11: 191-200.
13. [13] Anderson T, Sung D, Badner B. Global Pharmaceuticals: Bernstein Monthly Drug Pipeline Report - March 2014. New York (NY): Sanford C Bernstein LLC 2014.
14. [14] DiMasi JA, Grabowski HG. R&D costs and returns to new drug development: a review of the evidence. In: Danzon P, Nicholson S. Eds. The Oxford Handbook of the Economics of the Biopharmaceutical Industry. Oxford: Oxford University Press 2012; pp. 21-46.
15. [15] Hansen RW. The pharmaceutical development process: Estimates of current development costs and times and the effects of regulatory change. In: Chien R. Ed. Issues in Pharmaceutical Economics. Lexington, M.A.: Lexington Books 1979; pp. 151-87.
16. [16] DiMasi, JA; Hansen, R; Grabowski, H; Lasagna, L. Cost of innovation in the pharmaceutical industry. J Health Econ 1991; 10: 107-42.
17. [17] DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003; 22: 151-85.
18. [18] Steward F, Wibberly G. Drug innovation - what's slowing it down? Nature. 1980; 284: 118-120.
19. [19] Paul SM, Mytelka DS, Dunwiddie CT, et al.How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010: 203-14.
20. [20] Getz KA, Wenger J, Campo RA, Seguine ES, Kaitin KI. Assessing the impact of protocol design changes on clinical trial performance. Am J Ther 2008; 15: 450-57.
21. [21] Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 2004; 3: 417-29.
22. [22] Tufts Center for the Study of Drug Development. Growing Protocol Design Complexity Stresses Investigators, Volunteers. Report No.: 10.1. Medford (MA): Tufts University 2008.
23. [23] Tufts Center for the Study of Drug Development. Rising Protocol Complexity, Execution Burden Varies Widely by Phase and TA. Report No.: 12.3. Medford (MA): Tufts University 2010.
24. [24] Eichler HG, Oye K, Baird LG, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012; 91: 426-37.
25. [25] FDA. Guidance for Industry: Expedited Programs for Serious Conditions - Drugs and Biologics. 2014; Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf [cited: Oct 2014].
26. [26] Asbury CH. The Orphan Drug Act: The first 7 years. JAMA - J Am Med Assoc 1991; 265: 893-97.
27. [27] Office of the Inspector General. The Orphan Drug Act: Implementation and Impact. San Francisco, (CA): Office of the Inspector General 2001.
28. [28] Tait J, Milne C. Evolution along the government-governance continuum: FDA's Orphan Products and Fast Track programs as exemplars of "what works" for innovation and regulation. Food Drug Law J 2007; 64: 733-53.
29. [29] European Medicines Agency. Orphan Designation. 2014; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp [cited: Oct 2014].
30. [30] European Medicines Agency. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. 2013; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500153953.pdf [cited: Oct 2014].
31. [31] Woodcock J. Evidence vs. access: Can twenty-first-century drug regulation refine the tradeoffs? Clin Pharmacol Ther 2012; 91: 378-80.
32. [32] Forda SR, Bergstrom R, Chlebus M, Barker R, Andersen PH. Priorities for improving drug research, development and regulation. Nat Rev Drug Discov 2013; 12: 247-248.
33. [33] Baird LG, Trusheim MR, Eichler HG, Berndt ER, Hirsch G. Comparison of stakeholder metrics for traditional and adaptive development and licensing approaches to drug development. Thera Innova Regulat Sci 2013; 47: 474-83.
34. [34] Eichler HG, Roberts S, Stokes A. Uniting strategy and science. Regulatory Rapporteur 2014; 11: 11-13.
35. [35] European Medicines Agency. Adaptive licensing. 2014; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000601.jsp&mid=WC0b01ac05807d58ce [cited: Oct 2014].
36. [36] Grabowski HG, Vernon JA, DiMasi JA. Returns on research and development for 1990s new drug introductions. PharmacoEconomics 2002; 20 Suppl. 3: 11-29.
37. [37] Public Citizen. Rx R&D Myths: The Case Against the Drug Industry's R&D "Scare Card". 2001; Available from: http://www.citizen.org/documents/acfdc.pdf [cited: Oct 2014].
38. [38] DiMasi JA, Hansen RW, Grabowski H G. Assessing claims about the cost of new drug development: A critique of the Public Citizen and TB Alliance reports. 2004; Available from: http://csdd.tufts.edu/files/uploads/assessing_claims.pdf. [cited: Oct 2014].
39. [39] Light DW, Warburton RN. Extraordinary claims require extraordinary evidence: comment. J Health Econ 2005; 24: 1030-33.
40. [40] Light DW, Warburton RN. Setting the record straight in reply by DiMasi, Hansen, and Grabowski. J Health Econ 2005; 24: 1045-8.
41. [41] DiMasi JA, Hansen RW, Grabowski HG. Extraordinary claims require extraordinary evidence: reply. J Health Econ 2005; 24: 1034-44.
42. [42] DiMasi JA, Hansen RW, Grabowski HG. Setting the record straight on setting the record straight: response to Light and Warburton rejoinder. J Health Econ 2005; 24: 1049-53.
43. [43] Sertkaya A, Eyraud J, Birkenbach A, et al. Analytical Framework for Examining the Value of Antibacterial Products. Lexington (MA): Eastern Research Group 2014.
44. [44] Grabowski HG, Vernon JA. A new look at returns and risks to pharmaceutical R&D. Manage Sci 1990; 36: 804-21.
45. [45] Grabowski HG, Vernon JA. Returns to R&D on new drug introductions in the 1980s. J Health Econ 1994; 13: 383-06.
46. [46] Joglekar P, Paterson ML. A closer look at the returns and risks of pharmaceutical R&D. J Health Econ. 1 1986; 6: 153-77.
47. [47] DiMasi JA, Grabowski HG, Vernon JA. R&D costs and returns by therapeutic category. Drug Inf J 2004; 38: 211-23.
48. [48] DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: Is biotech different? Manage Decis Econ 2007; 28: 469-79.
49. [49] Baily M. Research and development costs and returns: The U.S. pharmaceutical industry. J Polit Econ 1972; 80: 75-85.
50. [50] Schwartzman D. Pharmaceutical R&D expenditures and rates of return. In Helms R. Drug Development and Marketing. The American Enterprise Institute 1975; 63-80.
51. [51] Statman M. Competition in the pharmaceutical industry: The declining profitability of drug innovation. Washington DC; 1983.
52. [52] Baber W, Kang S. Estimates of economic rates of return for the U.S. pharmaceutical industry, 1976-1987. J Account Public Pol 1996; 15: 327-46.
53. [53] Sheck L, Cox C, Davis HT, Trimble AG, Wardell WM, Hansen RW. Success rates in the United States drug development system. Clin Pharmacol Ther 1984; 36: 574-583.
54. [54] DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 1995; 58: 1-14.
55. [55] DiMasi, JA. Risks in new drug development: Approval success rates for investigational drugs. Clin Pharmacol Ther 2001; 69: 297-307.
56. [56] Abrantees-Metz RM, Adams CP, Metz AD. Pharmaceutical devel opment phases: A duration analysis. Working Paper No. 274. Washington (DC): Federal Trade Commission: Bureau of Economics 2004.
57. [57] DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: Success rates for investigational drugs. Clin Pharmacol Ther 2010; 87: 272-7.
58. [58] Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol 2014; 32: 40-51.
59. [59] Grabowski HG, Vernon JA. A sensitivity analysis of expected profitability of pharmaceutical research and development. Manage Decis Econ 1982; 3: 36-40.
60. [60] Scherer F, Harhoff D. Technology policy for a world of skewdistributed outcomes. Res Policy 2000; 29: 559-66.
61. [61] Grabowski HG, Vernon JA, DiMasi JA. Returns on research and development for 1990s new drug introductions. PharmacoEconomics 2002; 20 Suppl. 3: 11-29.
62. [62] Dimitri N. Pricing pharmaceutical compounds under development. Trends Pharmacol Sci 2014; 35: 216-7.
63. [63] European Medicines Agency. Assessment Report for Acomplia. [Online].; 2009 [cited 2014]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000666/WC500021280.pdf.
64. [64] Novartis. Gilenya. Full Prescribing Information. 2014; Available from: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf[cited: Oct 2014].
65. [65] Budde K, Schutz M, Glander P, et al. FTY720 (fingolimod) in renal transplantation. Clin Transplant 2006; 20(s17): 16-24.
66. [66] Aggarwal A, Ginsburg O, Fojo T. Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US. J Cancer Policy 2014; 2: 1-11.
67. [67] Hall B, Jaffe A, Trajtenberg M. Market Value and Patent Citations. RAND J Econ 2005; 6: 16-38.
68. [68] Kesselheim AS, Avorn J. The most transformative drugs of the past 25 years: a survey of physicians. Nat Rev Drug Discov 2013; 12: 425-31.
69. [69] Cha M, Rifai B, Sarraf P. Pharmaceutical forecasting: Throwing darts? Nat Rev Drug Discov 2013; 12: 737-8.
70. [70] DeMonaco HJ, Ali A, Von Hippel E. The major role of clinicians in the discovery of off-label drug therapies. Pharmacotherapy. 2006; 26: 323-32.
71. [71] Roin B. Solving The Problem of New Uses. 2014; Available from: http://nrs.harvard.edu/urn-3:HUL.InstRepos:11189865 [cited: Oct 2014]
72. [72] Le Fanu J. The Rise and Fall of Modern Medicine London: Little Brown; 1999.
73. [73] Healy D. The Antidepressant Era: Harvard University Press; 1997.
74. [74] Mittra J. Repairing the "broken middle" of the health innovation pathway. Sci Technol Studies 2013; 3: 103-123.
75. [75] IDSA. IDSA comments on FDA draft guidance for industry on hospital-acquired and ventilator-associated bacterial pneumonia. Federal Register 73106, November 29, 2010; Available from: http://www.idsociety.org/uploadedFiles/IDSA/Policy_and_Advocacy/Current_Topics_and_Issues/Advancing_Product_Research_and_Development/Bad_Bugs_No_Drugs/Position_Papers/IDSA%20Comments%20on%20HABP%20and%20VABP.pdf [cited: Oct 2014].
76. [76] IDSA. IDSA comments on draft guidance for hospital-acquired and ventilator-associated bacterial pneumonia. Docket FDA-2010-D- 0589. 2014; Available from: http://www.idsociety.org/uploaded-Files/IDSA/Policy_and_Advocacy/Current_Topics_and_Issues/Advancing_Product_Research_and_Development/Bad_Bugs_No_Drugs/Position_Papers/IDSA%20Comments%20on%20Draft%20GFI%20HABP-VABP%20080514.pdf [cited: Oct 2014].
77. [77] FDA. Guidance for Industry Antibacterial Therapies for Patients Disease. 2013; Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM359184.pdf [cited: Oct 2014].
78. [78] Porges G, Pancratov R, Shi W. Biotech: Meet the IPO Class of 2012-2014: Who Has What, How Far Along? Who Has Best Performance (So Far)? New York (NY): Sanford C. Bernstein LLC 2014.
79. [79] Buggy Y, Cornelius V, Wilton L, Shakir S. Risk of depressive episodes with rimonabant. Drug Safety 2011; 34: 501-9.